Sherman Mark E, Wang Sophia S, Carreon Joseph, Devesa Susan S
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20892-7374, USA.
Cancer. 2005 Mar 15;103(6):1258-64. doi: 10.1002/cncr.20877.
In the United States, detection of squamous carcinoma in situ (CIS) by screening has led to reduced rates for invasive squamous carcinoma and lower mortality. Adenocarcinoma in situ (AIS) rates also have increased, but invasive cervical adenocarcinoma rates have not declined similarly. To make inferences about the effectiveness of screening, the authors assessed mortality trends for squamous and adenocarcinoma in relation to incidence of these tumors, incidence of their precursors and survival.
Using data from the Surveillance, Epidemiology, and End Results program (SEER), the authors tabulated incidence per 10(5) woman-years for invasive carcinomas (1976-2000) and for CIS and AIS (1976-1995) by age (< 50 years, > or = 50 years) and race (whites, blacks). Cumulative relative survival rates were tabulated for 1976-1995 and mortality rates were estimated for 1986-2000.
Among all groups, CIS rates approximately doubled whereas rates for invasive squamous carcinoma declined. Among younger whites, mortality declined from 1.12 to 0.93, and for older whites, mortality decreased from 5.02 to 3.82. Among younger blacks, mortality for squamous carcinoma decreased from 2.69 to 1.96. Among older blacks, the mortality rates declined from 14.88 to 9.15. Although AIS rates have increased dramatically among whites (all ages) and younger blacks, adenocarcinoma incidence and mortality rates have not changed greatly. Survival for patients did not change greatly within these age-race groups.
The authors concluded that increases in CIS seemed disproportionately large compared with improvements in mortality rates for squamous carcinoma. Despite increased reporting of AIS, declines in mortality for cervical adenocarcinoma have not been demonstrated conclusively. However, future analyses are required to evaluate these trends more completely.
在美国,通过筛查发现原位鳞状细胞癌(CIS)已导致浸润性鳞状细胞癌发病率降低和死亡率下降。原位腺癌(AIS)的发病率也有所上升,但浸润性宫颈腺癌的发病率并未相应下降。为了推断筛查的有效性,作者评估了鳞状细胞癌和腺癌的死亡率趋势与这些肿瘤的发病率、其癌前病变的发病率及生存率之间的关系。
作者利用监测、流行病学和最终结果计划(SEER)的数据,按年龄(<50岁、≥50岁)和种族(白人、黑人)列出了1976 - 2000年浸润性癌以及1976 - 1995年CIS和AIS每10(5)女性年的发病率。列出了1976 - 1995年的累积相对生存率,并估计了1986 - 2000年的死亡率。
在所有组中,CIS发病率大约翻了一番,而浸润性鳞状细胞癌的发病率下降。在较年轻的白人中,死亡率从1.12降至0.93,在较年长的白人中,死亡率从5.02降至3.82。在较年轻的黑人中,鳞状细胞癌的死亡率从2.69降至1.96。在较年长的黑人中,死亡率从14.88降至9.15。尽管白人(所有年龄段)和较年轻的黑人中AIS发病率大幅上升,但腺癌的发病率和死亡率变化不大。在这些年龄 - 种族组中,患者的生存率变化不大。
作者得出结论,与鳞状细胞癌死亡率的改善相比,CIS的增加似乎不成比例地大。尽管AIS的报告有所增加,但宫颈腺癌死亡率的下降尚未得到确凿证实。然而,需要进一步分析以更全面地评估这些趋势。